MedPath

Efficacy and safety of a switch to latanoprost 0.005% + timolol maleate 0.5% fixed combination eyedrops from tafluprost 0.0015% monotherapy.

Not Applicable
Conditions
glaucoma
Registration Number
JPRN-UMIN000017687
Lead Sponsor
Department of Ophthalmology, Keio University School of Medicine
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
50
Inclusion Criteria

Not provided

Exclusion Criteria

# Angle closure # History of glaucoma surgery # Bronchial asthma

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
intraocuar pressure
Secondary Outcome Measures
NameTimeMethod
complications
© Copyright 2025. All Rights Reserved by MedPath